Literature DB >> 2004167

Thrombolytic treatment for recurrent myocardial infarction.

H White.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2004167      PMCID： PMC1669357          DOI： 10.1136/bmj.302.6774.429

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking.

Authors:  J T Rivers; H D White; D B Cross; B F Williams; R M Norris
Journal:  J Am Coll Cardiol       Date:  1990-08       Impact factor: 24.094

2.  GISSI-2 and the heparin controversy.

Authors:  H D White
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

3.  Antistreptokinase titres after intravenous streptokinase.

Authors:  S Jalihal; G K Morris
Journal:  Lancet       Date:  1990-01-27       Impact factor: 79.321

4.  Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.

Authors:  H D White; D B Cross; B F Williams; R M Norris
Journal:  Br Heart J       Date:  1990-09

5.  Assessment of anti-streptokinase antibody levels in human sera using a microradioimmunoassay procedure.

Authors:  D M Moran; R Standring; E A Lavender; G S Harris
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

6.  Thrombolytic therapy with streptokinase using a standard dosage scheme.

Authors:  M Verstraete; J Vermylen; A Amery; C Vermylen
Journal:  Br Med J       Date:  1966-02-19

7.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

8.  Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.

Authors:  H D White; J T Rivers; A H Maslowski; J A Ormiston; M Takayama; H H Hart; D N Sharpe; R M Whitlock; R M Norris
Journal:  N Engl J Med       Date:  1989-03-30       Impact factor: 91.245
  8 in total
  5 in total

1.  Immunoglobulin response to intravenous streptokinase in acute myocardial infarction.

Authors:  S C Grant
Journal:  Br Heart J       Date:  1992-05

2.  Thrombolytic treatment for recurrent myocardial infarction.

Authors:  N J Dudley; E Burns
Journal:  BMJ       Date:  1991-03-30

Review 3.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 4.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 5.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.